24 September 2013 in Genome Biology
Background: Although aberrant DNA methylation has been observed previously in acute lymphoblastic leukemia (ALL), the patterns of differential methylation have not been comprehensively determined in all subtypes of ALL on a genome-wide scale. The relationship between DNA methylation, cytogenetic background, drug resistance and relapse in ALL is poorly understood. Results: We surveyed the DNA methylation levels of 435,941 CpG sites in samples from 764 children at diagnosis of ALL and from 27 children at relapse. This survey uncovered four characteristic methylation signatures. First, compared with control blood cells, the methylomes of ALL cells shared 9,406 predominantly hypermethylated CpG sites, independent of cytogenetic background. Second, each cytogenetic subtype of ALL displayed a unique set of hyper- and hypomethylated CpG sites. The CpG sites that constituted these two signatures differed in their functional genomic enrichment to regions with marks of active or repressed chromatin. Third, we identified subtype-specific differential methylation in promoter and enhancer regions that were strongly correlated with gene expression. Fourth, a set of 6,612 CpG sites was predominantly hypermethylated in ALL cells at relapse, compared with matched samples at diagnosis. Analysis of relapse-free survival identified CpG sites with subtype-specific differential methylation that divided the patients into different risk groups, depending on their methylation status. Conclusions: Our results suggest an important biological role for DNA methylation in the differences between ALL subtypes and in their clinical outcome after treatment.
1 February 2016 in The American Journal of Human Genetics
8 December 2010 in Pediatric Blood & Cancer
O(On Behalf Of The Nordic Society Of Paediatric Haematology And Oncology (Nopho)
On Behalf Of The Nordic Society Of Paediatric Haematology And Oncology (Nopho)
+5
20 April 2007 in Journal of Clinical Oncology
Purpose: The aim of the study was to determine the incidence of and clinical risk factors for radiographic osteonecrosis (ON) in children treated for acute lymphoblastic leukemia (ALL) using the Nordic ALL protocols. Patients and Methods: Ninety-seven consecutive patients with childhood ALL were studied prospectively by magnetic resonance imaging (MRI) of the lower extremities at the end of the treatment. Results: Twenty-three (24%) of the 97 patients had ON. Seven of the patients (30%) were symptomatic, and three patients (13%) required surgical interventions. Multiple logistic regression analysis showed that high body mass index (BMI; P = .04), female sex (P = .01), older age at diagnosis (P < .001), and higher cumulative dexamethasone dose (P = .03) were independent risk factors for radiographic ON. The cumulative prednisone dose did not differ significantly between the patients with and without ON. The incidence of radiographic ON decreased significantly, from 36% to 7%, when the duration of dexamethasone exposure during the delayed-intensification phase was shortened from 3 to 4 weeks to 2 weeks with a taper (P = .001). Conclusion: ON as determined by MRI was found to be a common complication in children and adolescents after treatment with the Nordic ALL protocols. Revision of the ALL protocols by shortening the single exposure to dexamethasone has diminished the risk for ON remarkably. High BMI was identified as a new significant risk factor for ON.
5 September 2002 in Cancer
BACKGROUND: Positron emission tomography (PET) scans of primary brain tumors were performed in pediatric patients to examine whether metabolic characteristics could be used as an index of clinical aggressiveness.METHODS: Twenty‐seven pediatric patients with untreated primary central nervous system neoplasms were studied with PET scans using 2‐[18F] fluoro‐2‐deoxy‐D‐glucose (FDG) and/or L‐[methyl‐11C] methionine (MET). Metabolic characteristics as assessed with FDG and MET standardized uptake values (SUV) and SUV‐to‐normal brain ratios were compared with histopathology and selected histochemical features such as proliferation activity (Ki‐67MIB‐1) and apoptotic, vascular, and cell density indices. The median followup time was 43 months.RESULTS: The accumulation of both FDG and MET was significantly higher in high‐grade than in low‐grade tumors, but a considerable overlap was found. The accumulation of both tracers was associated positively with age. High‐grade tumors showed higher proliferative activity and vascularity than the low‐grade tumors. In univariate analysis, FDG‐PET, MET‐PET, and apoptotic index were independent predictors of event‐free survival.CONCLUSION: We found that both FDG and MET uptake in pediatric brain tumors are associated with malignancy grade. However, no clear limits of SUVs and SUV‐to‐normal brain ratios can be set between low‐grade and high‐grade tumors, which makes the assessment of malignancy grade using metabolic imaging with PET scan difficult in individual cases. Although FDG‐PET and MET‐PET do not compensate for histopathologic evaluation, they may give valuable additional information especially if invasive procedures to obtain histopathologic samples are not feasible. Cancer 2002;95:1376–86. © 2002 American Cancer Society.DOI 10.1002/cncr.10798
1 October 2009 in Neuro-Oncology
While the prognosis of acute childhood leukemia has improved, long-term survivors are increasingly experiencing late effects of the treatment. Crania